Comparison of Propranolol and Venlafaxine in Treatment of Vestibular Migraine

• Status: Completed
• Trial end date: 2014-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The presented study aims to compare effectivity of propranolol with effectivity of venlafaxine in escalating dose in subjects with vestibular migraine (VM) over a period of 12 weeks. The study population consisted of subjects diagnosed definite VM according to criteria of Bárány Society and Migraine Classification Subcommittee of the International Headache Society (IHS). Effectivity of therapy was measured by Dizziness Handicap Inventory (DHI), number of vertiginous attack of last month and visual analogue scale (VAS) reported dizziness related Quality of Life (QOL). Beck Anxiety Inventory (BAI) and Beck Depression Inventory (BDI) were also used to determine psychiatric improvement played role in response to therapy in venlafaxine treatment arm.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Haseki Training and Research Hospital
• Treatments: Propranolol; Venlafaxine Hydrochloride

Criteria

Inclusion Criteria:

• vestibular migraine does not respond lifestyle and dietary modification

Exclusion Criteria:

• known allergic reaction to venlafaxine or propranolol

• under the care of psychiatrist

• pregnancy or intention to become pregnant

• presence significant illness or medical condition such as cancer, liver or kidney failure

• certain medical conditions with possible adverse effects with propranolol or venlafaxine following as: AV block or bradyarrhythmia; astma or COPD; diabetes mellitus.